Zomedica Pharmaceuticals Corp Stock Price Declines Today

 Zomedica Pharmaceuticals Corp Stock Price Declines Today

The stock of Zomedica Pharmaceuticals Corp (CVE:ZOM) is a huge mover today! About 9,710 shares traded hands or 11.97% up from the average. Zomedica Pharmaceuticals Corp (CVE:ZOM) has risen 6.00% since October 30, 2016 and is uptrending. It has outperformed by 0.74% the S&P500.
The move comes after 8 months negative chart setup for the $106.82 million company. It was reported on Nov, 29 by Barchart.com. We have $1.29 PT which if reached, will make CVE:ZOM worth $6.41 million less.

More notable recent Zomedica Pharmaceuticals Corp (CVE:ZOM) news were published by: Globenewswire.com which released: “Zomedica Pharmaceuticals Corp. Announces Third Quarter 2016 Financial Results” on November 22, 2016, also Marketwatch.com with their article: “Zomedica Pharmaceuticals Corp. Opens the Market” published on May 03, 2016, Globenewswire.com published: “Zomedica Pharmaceuticals Corp. Announces First Quarter 2016 Financial Results …” on May 26, 2016. More interesting news about Zomedica Pharmaceuticals Corp (CVE:ZOM) were released by: Reuters.com and their article: “BRIEF-Zomedica Pharmaceuticals Q3 loss per share $0.01” published on March 31, 2016 as well as Globenewswire.com‘s news article titled: “Zomedica Announces Completion of Qualifying Transaction” with publication date: April 27, 2016.

Zomedica Pharmaceuticals Corp., formerly Wise Oakwood Ventures Inc., is a Canada veterinary pharmaceutical company. The company has a market cap of $106.82 million. The Firm focuses on health and wellness solutions for companion animals, such as canine, feline and equine. It currently has negative earnings. The Firm is engaged in building a portfolio of products comprised of the discovery, development and commercialization of drugs alongside drug delivery systems, devices and diagnostics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment